Federica Fogacci
@federicafogacci.bsky.social
@Unibo & Brisighella Heart Study Group | SoMe Ambassador and Young Fellow of the European Atherosclerosis Society #EAS | SoMe Editor of Atherosclerosis
Week 1 calendar for the #RoadToEASCongress2026 Challenge 🔙
Save it, pick the daily prompt, and share your favorite memories from past @EASCongress editions.
Day 1⃣ starts tomorrow:
Your first EAS Congress — when and where?
#EASCongress2026
@eassociety.bsky.social #EASSoMe #CvPrev
Save it, pick the daily prompt, and share your favorite memories from past @EASCongress editions.
Day 1⃣ starts tomorrow:
Your first EAS Congress — when and where?
#EASCongress2026
@eassociety.bsky.social #EASSoMe #CvPrev
May 9, 2026 at 7:33 PM
Week 1 calendar for the #RoadToEASCongress2026 Challenge 🔙
Save it, pick the daily prompt, and share your favorite memories from past @EASCongress editions.
Day 1⃣ starts tomorrow:
Your first EAS Congress — when and where?
#EASCongress2026
@eassociety.bsky.social #EASSoMe #CvPrev
Save it, pick the daily prompt, and share your favorite memories from past @EASCongress editions.
Day 1⃣ starts tomorrow:
Your first EAS Congress — when and where?
#EASCongress2026
@eassociety.bsky.social #EASSoMe #CvPrev
🚀 Starting tomorrow: the #RoadToEASCongress2026 Challenge!
14 days of memories, science, community, and excitement on the way to #EASCongress2026.
📅 May 10–23
📍 One prompt per day
💬 Join using #RoadToEASCongress2026
Tag a colleague who should take part! @eassociety.bsky.social #EASSoMe
14 days of memories, science, community, and excitement on the way to #EASCongress2026.
📅 May 10–23
📍 One prompt per day
💬 Join using #RoadToEASCongress2026
Tag a colleague who should take part! @eassociety.bsky.social #EASSoMe
May 9, 2026 at 2:51 PM
🚀 Starting tomorrow: the #RoadToEASCongress2026 Challenge!
14 days of memories, science, community, and excitement on the way to #EASCongress2026.
📅 May 10–23
📍 One prompt per day
💬 Join using #RoadToEASCongress2026
Tag a colleague who should take part! @eassociety.bsky.social #EASSoMe
14 days of memories, science, community, and excitement on the way to #EASCongress2026.
📅 May 10–23
📍 One prompt per day
💬 Join using #RoadToEASCongress2026
Tag a colleague who should take part! @eassociety.bsky.social #EASSoMe
Lp(a) doesn't just add risk-it reframes it (often a lifelong, family conversation). The question isn't "should we test?" but how we implement testing so results are clear and actionable @lipidjournal.bsky.social
🔗 lipidjournal.com/article/S193...
@afgciceromd.bsky.social @eassociety.bsky.social
🔗 lipidjournal.com/article/S193...
@afgciceromd.bsky.social @eassociety.bsky.social
December 21, 2025 at 10:08 AM
Lp(a) doesn't just add risk-it reframes it (often a lifelong, family conversation). The question isn't "should we test?" but how we implement testing so results are clear and actionable @lipidjournal.bsky.social
🔗 lipidjournal.com/article/S193...
@afgciceromd.bsky.social @eassociety.bsky.social
🔗 lipidjournal.com/article/S193...
@afgciceromd.bsky.social @eassociety.bsky.social
Feeling honored to be recognized for the 3rd consecutive year on Stanford University and Elsevier’s Top 2% Scientists list. #Grateful to my incredible colleagues and mentors — thank you for your support as we keep pushing boundaries and growing together @unibo.it @eassociety.bsky.social #CvPrev
September 28, 2025 at 8:28 AM
Feeling honored to be recognized for the 3rd consecutive year on Stanford University and Elsevier’s Top 2% Scientists list. #Grateful to my incredible colleagues and mentors — thank you for your support as we keep pushing boundaries and growing together @unibo.it @eassociety.bsky.social #CvPrev
🎤 First time speaking at #RiminiWellness — I shared some insights on non-pharmacological strategies for managing dyslipidemia. Thanks for the invitation and the audience’s practical questions! Science & wellness grow stronger together #RW25 #CvPrev
June 1, 2025 at 11:07 AM
🎤 First time speaking at #RiminiWellness — I shared some insights on non-pharmacological strategies for managing dyslipidemia. Thanks for the invitation and the audience’s practical questions! Science & wellness grow stronger together #RW25 #CvPrev
Had the pleasure of delivering a talk at the ANCE Interprovincial Congress on CV prevention & dyslipidemia management in low-risk patients. Empowering 👫 today means healthier tomorrows—for them and the healthcare system. Grateful for the warm welcome! #EASSoMe @eassociety.bsky.social
May 29, 2025 at 8:57 AM
Had the pleasure of delivering a talk at the ANCE Interprovincial Congress on CV prevention & dyslipidemia management in low-risk patients. Empowering 👫 today means healthier tomorrows—for them and the healthcare system. Grateful for the warm welcome! #EASSoMe @eassociety.bsky.social
Great to have Prof. Jung Hyun Choi with us in Bologna during her journey from South Korea to Milan for the ESH Annual Congress. A meaningful exchange ahead of #ESH2025 — and a perfect occasion to let her try tagliatelle al ragù! 🇮🇹🍝 @afgciceromd.bsky.social @unibo.bsky.social
May 21, 2025 at 9:15 PM
Great to have Prof. Jung Hyun Choi with us in Bologna during her journey from South Korea to Milan for the ESH Annual Congress. A meaningful exchange ahead of #ESH2025 — and a perfect occasion to let her try tagliatelle al ragù! 🇮🇹🍝 @afgciceromd.bsky.social @unibo.bsky.social
How do we act?
1⃣ Start w/ lifestyle changes—always the foundation
2⃣ Add the right medications when needed
3⃣ In severe cases, consider surgery
It’s not one-size-fits-all: treatment must match the stage and the organs involved #EASSoMe @eassociety.bsky.social
1⃣ Start w/ lifestyle changes—always the foundation
2⃣ Add the right medications when needed
3⃣ In severe cases, consider surgery
It’s not one-size-fits-all: treatment must match the stage and the organs involved #EASSoMe @eassociety.bsky.social
May 12, 2025 at 11:40 AM
How do we act?
1⃣ Start w/ lifestyle changes—always the foundation
2⃣ Add the right medications when needed
3⃣ In severe cases, consider surgery
It’s not one-size-fits-all: treatment must match the stage and the organs involved #EASSoMe @eassociety.bsky.social
1⃣ Start w/ lifestyle changes—always the foundation
2⃣ Add the right medications when needed
3⃣ In severe cases, consider surgery
It’s not one-size-fits-all: treatment must match the stage and the organs involved #EASSoMe @eassociety.bsky.social
Excess fat can silently damage your liver, 🫀, kidneys, pancreas—not just 📈 your weight.
That’s why early, multi-organ screening is key. Catch risks before they turn into disease - because progression to later stages means a much higher risk of death ⚠️ @eassociety.bsky.social #EASSoMe
That’s why early, multi-organ screening is key. Catch risks before they turn into disease - because progression to later stages means a much higher risk of death ⚠️ @eassociety.bsky.social #EASSoMe
May 12, 2025 at 11:40 AM
Excess fat can silently damage your liver, 🫀, kidneys, pancreas—not just 📈 your weight.
That’s why early, multi-organ screening is key. Catch risks before they turn into disease - because progression to later stages means a much higher risk of death ⚠️ @eassociety.bsky.social #EASSoMe
That’s why early, multi-organ screening is key. Catch risks before they turn into disease - because progression to later stages means a much higher risk of death ⚠️ @eassociety.bsky.social #EASSoMe
📊 Shocking stat: Over 75% of people in the UK Biobank show early signs of systemic metabolic disorders. The new @eassociety.bsky.social staging system (Stage 1–3) helps detect risks early—so we can act before it’s too late. Prevention starts now 🙌 #EASSoMe @cibiocm.bsky.social
May 12, 2025 at 11:40 AM
📊 Shocking stat: Over 75% of people in the UK Biobank show early signs of systemic metabolic disorders. The new @eassociety.bsky.social staging system (Stage 1–3) helps detect risks early—so we can act before it’s too late. Prevention starts now 🙌 #EASSoMe @cibiocm.bsky.social
The brand-new EAS Consensus is here—offering a game-changing, clinically actionable roadmap to tackle met disorders linked to obesity. Time to move from treating symptoms to a full-body, root-cause approach
@eassociety.bsky.social @cibiocm.bsky.social #EASSoMe
@eassociety.bsky.social @cibiocm.bsky.social #EASSoMe
May 12, 2025 at 11:40 AM
The brand-new EAS Consensus is here—offering a game-changing, clinically actionable roadmap to tackle met disorders linked to obesity. Time to move from treating symptoms to a full-body, root-cause approach
@eassociety.bsky.social @cibiocm.bsky.social #EASSoMe
@eassociety.bsky.social @cibiocm.bsky.social #EASSoMe
#MyEAS2025 The live discussion of my case on statin intolerance at #EASCongress2025 was truly exciting! The EAS Stage was packed—much more than the photo shows—and the audience was incredibly engaged. Big thanks to everyone who joined for this rewarding discussion! @eassociety.bsky.social
May 8, 2025 at 11:35 AM
#MyEAS2025 The live discussion of my case on statin intolerance at #EASCongress2025 was truly exciting! The EAS Stage was packed—much more than the photo shows—and the audience was incredibly engaged. Big thanks to everyone who joined for this rewarding discussion! @eassociety.bsky.social
#MyEAS2025 Honored to join as a panelist at #EASCongress2025 in a session on the power of SoMe in science & networking. Sharing how these platforms launched my journey into ath was truly exciting—and I hope it inspires other early-career researchers! @eassociety.bsky.social @katioorni.bsky.social
May 8, 2025 at 10:44 AM
#MyEAS2025 Honored to join as a panelist at #EASCongress2025 in a session on the power of SoMe in science & networking. Sharing how these platforms launched my journey into ath was truly exciting—and I hope it inspires other early-career researchers! @eassociety.bsky.social @katioorni.bsky.social
💡 Key takeaway in one line! #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
Excited to share the latest breakthroughs in lipid research and clinical practice. Here’s a quick snapshot of yesterday's late-breaking findings 👇
Excited to share the latest breakthroughs in lipid research and clinical practice. Here’s a quick snapshot of yesterday's late-breaking findings 👇
May 8, 2025 at 9:07 AM
💡 Key takeaway in one line! #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
Excited to share the latest breakthroughs in lipid research and clinical practice. Here’s a quick snapshot of yesterday's late-breaking findings 👇
Excited to share the latest breakthroughs in lipid research and clinical practice. Here’s a quick snapshot of yesterday's late-breaking findings 👇
The BROADWAY study results are out now in @nejm.org, published simultaneously with their presentation at #EASCongress2025 🙌 So if you missed Prof. Nicholls' talk—you can catch up here www.nejm.org/doi/full/10....
#EASCongress2025 #MyEAS2025 @maciejbanach.bsky.social @eassociety.bsky.social
#EASCongress2025 #MyEAS2025 @maciejbanach.bsky.social @eassociety.bsky.social
May 8, 2025 at 9:05 AM
The BROADWAY study results are out now in @nejm.org, published simultaneously with their presentation at #EASCongress2025 🙌 So if you missed Prof. Nicholls' talk—you can catch up here www.nejm.org/doi/full/10....
#EASCongress2025 #MyEAS2025 @maciejbanach.bsky.social @eassociety.bsky.social
#EASCongress2025 #MyEAS2025 @maciejbanach.bsky.social @eassociety.bsky.social
Obicetrapib was well tolerated in the BROADWAY study. Long-term effects on CV outcomes will be evaluated in the ongoing PREVAIL trial—but current results suggest it holds considerable promise for improving lipid control in high CV risk patients #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
May 8, 2025 at 9:03 AM
Obicetrapib was well tolerated in the BROADWAY study. Long-term effects on CV outcomes will be evaluated in the ongoing PREVAIL trial—but current results suggest it holds considerable promise for improving lipid control in high CV risk patients #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
BROADWAY Study: Additionally, obicetrapib led to a placebo-adj 33.5% reduction in Lp(a), independent of its effects on other lipid parameters and HDL-C increase. The broader lipid effects are also very encouraging #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
May 8, 2025 at 9:02 AM
BROADWAY Study: Additionally, obicetrapib led to a placebo-adj 33.5% reduction in Lp(a), independent of its effects on other lipid parameters and HDL-C increase. The broader lipid effects are also very encouraging #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
BROADWAY study: Obicetrapib, added to maximally tolerated LLT in high-risk CV patients, reduced placebo-adjusted LDL-C by 32.6% at day 84 and 24% at day 365, with 51% of patients reaching LDL-C <55 mg/dL #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
May 8, 2025 at 9:01 AM
BROADWAY study: Obicetrapib, added to maximally tolerated LLT in high-risk CV patients, reduced placebo-adjusted LDL-C by 32.6% at day 84 and 24% at day 365, with 51% of patients reaching LDL-C <55 mg/dL #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
The results of the TANDEM trial have been published in @thelancet.bsky.social , simultaneously with their presentation at the #EASCongress2025! Read the full article here: doi.org/10.1016/S014...
@erinmichos.bsky.social @eassociety.bsky.social #MyEAS2025
@erinmichos.bsky.social @eassociety.bsky.social #MyEAS2025
May 8, 2025 at 8:59 AM
The results of the TANDEM trial have been published in @thelancet.bsky.social , simultaneously with their presentation at the #EASCongress2025! Read the full article here: doi.org/10.1016/S014...
@erinmichos.bsky.social @eassociety.bsky.social #MyEAS2025
@erinmichos.bsky.social @eassociety.bsky.social #MyEAS2025
While the TANDEM trial has limitations—short follow-up, mainly White participants, and no systematic CV event tracking—if approved, the fixed-dose combo could still offer a valuable new oral option for lowering LDL-C in patients on maximally tolerated LLT #EASCongress2025 @eassociety.bsky.social
May 8, 2025 at 8:57 AM
While the TANDEM trial has limitations—short follow-up, mainly White participants, and no systematic CV event tracking—if approved, the fixed-dose combo could still offer a valuable new oral option for lowering LDL-C in patients on maximally tolerated LLT #EASCongress2025 @eassociety.bsky.social
Beyond LDL-C, the TANDEM trial showed very encouraging results on ApoB and a high proportion of patients reaching lipid targets. The fixed-dose combo was also well tolerated #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
May 8, 2025 at 8:56 AM
Beyond LDL-C, the TANDEM trial showed very encouraging results on ApoB and a high proportion of patients reaching lipid targets. The fixed-dose combo was also well tolerated #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
The TANDEM trial: the fixed-dose combo of obicetrapib + ezetimibe cut LDL-C by nearly 50%, with over 70% of participants reaching levels below 1.4 mmol/L. A promising step forward in lipid lowering! #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
May 8, 2025 at 8:55 AM
The TANDEM trial: the fixed-dose combo of obicetrapib + ezetimibe cut LDL-C by nearly 50%, with over 70% of participants reaching levels below 1.4 mmol/L. A promising step forward in lipid lowering! #EASCongress2025 #MyEAS2025 @eassociety.bsky.social
#EASCongress2025 Late Breakers - Key takeaway in one line! #MyEAS2025
Check out the slide below for a one-line summary of each late-breaking presentation — concise, clear, and all in one place 😎 @eassociety.bsky.social
Check out the slide below for a one-line summary of each late-breaking presentation — concise, clear, and all in one place 😎 @eassociety.bsky.social
May 5, 2025 at 3:51 PM
#EASCongress2025 Late Breakers - Key takeaway in one line! #MyEAS2025
Check out the slide below for a one-line summary of each late-breaking presentation — concise, clear, and all in one place 😎 @eassociety.bsky.social
Check out the slide below for a one-line summary of each late-breaking presentation — concise, clear, and all in one place 😎 @eassociety.bsky.social
Whether you're attending #EASCongress2025 remotely or in person, get 🛋️ — the Opening Ceremony is about to start! Right after, the Anitschkow Lecture by Prof. Ridker is the perfect way to kick off 4 💥 days of cutting-edge ath research and treatment @EASCongress @society_eas
May 4, 2025 at 5:09 PM
Whether you're attending #EASCongress2025 remotely or in person, get 🛋️ — the Opening Ceremony is about to start! Right after, the Anitschkow Lecture by Prof. Ridker is the perfect way to kick off 4 💥 days of cutting-edge ath research and treatment @EASCongress @society_eas
The posters are up! 🙌 It’s such an exciting moment to see our research shared with the #EASCongress2025 community. Can’t wait for all the inspiring conversations and new ideas that will come from these next few days!
@eassociety.bsky.social @afgciceromd.bsky.social #MyEAS2025
@eassociety.bsky.social @afgciceromd.bsky.social #MyEAS2025
May 4, 2025 at 5:07 PM
The posters are up! 🙌 It’s such an exciting moment to see our research shared with the #EASCongress2025 community. Can’t wait for all the inspiring conversations and new ideas that will come from these next few days!
@eassociety.bsky.social @afgciceromd.bsky.social #MyEAS2025
@eassociety.bsky.social @afgciceromd.bsky.social #MyEAS2025